Delayed administration of the GLP-1 receptor agonist liraglutide improves metabolic and functional recovery after cerebral ischemia in rats

Neuroscience Letters

Volumn 641, Issue , 2017, Pages 1-7

  Dong, Wenbin ^a   Miao, Yunping ^a   Chen, Aiying ^a   Cheng, Min ^a   Ye, Xiaodi ^a   Song, Fahuan ^b   Zheng, Gaoli ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cerebral ischemia; Glucose metabolism; Liraglutide; Neurological function; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; NEURON SPECIFIC NUCLEAR PROTEIN; VON WILLEBRAND FACTOR; ADENOSINE TRIPHOSPHATE; MEMBRANE PROTEIN; NERVE PROTEIN; NEUROPEPTIDE Y; TMEM59 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN METABOLISM; CONTROLLED STUDY; CONVALESCENCE; GLUCOSE METABOLISM; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MODIFIED NEUROLOGICAL SEVERITY SCORE; NEUROIMAGING; NEUROLOGIC DISEASE ASSESSMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; THERAPY DELAY; WESTERN BLOTTING; AGONISTS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EATING; ENERGY METABOLISM; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; ANIMALS; BRAIN ISCHEMIA; EATING; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LIRAGLUTIDE; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEUROPEPTIDE Y;

EID: 85010199549     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2017.01.045     Document Type: Article

References (27)

1. [1] Abeysinghe, H.C., Phillips, E.L., Chin-Cheng, H., Beart, P.M., Roulston, C.L., Modulating astrocyte transition after stroke to promote brain rescue and functional recovery: emerging targets include Rho kinase. Int. J. Mol. Sci., 17, 2016, 288.
2. [2] Briyal, S., Gulati, K., Gulati, A., Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res. 1427 (2012), 23–34.
3. [3] Briyal, S., Shah, S., Gulati, A., Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia. Neuroscience 281 (2014), 269–281.
4. [4] Chen, J., Li, Y., Wang, L., Zhang, Z., Lu, D., Lu, M., Chopp, M., Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 32 (2001), 1005–1011.
5. [5] Darsalia, V., Larsson, M., Nathanson, D., Klein, T., Nystrom, T., Patrone, C., Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. J. Cereb. Blood Flow Metab. 35 (2015), 718–723.
6. [6] Donnan, G.A., Fisher, M., Macleod, M., Davis, S.M., Stroke. Lancet 371 (2008), 1612–1623.
7. [7] During, M.J., Cao, L., Zuzga, D.S., Francis, J.S., Fitzsimons, H.L., Jiao, X., Bland, R.J., Klugmann, M., Banks, W.A., Drucker, D.J., Haile, C.N., Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9 (2003), 1173–1179.
8. [8] Evenson, K.R., Foraker, R.E., Morris, D.L., Rosamond, W.D., A comprehensive review of prehospital and in-hospital delay times in acute stroke care. Int. J. Stroke 4 (2009), 187–199.
9. [9] Feigin, V.L., Lawes, C.M., Bennett, D.A., Anderson, C.S., Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2 (2003), 43–53.
10. [10] Heiss, W.D., Radionuclide imaging in ischemic stroke. J. Nucl. Med. 55 (2014), 1831–1841.
11. [11] Hermann, D.M., Buga, A.M., Popa-Wagner, A., Neurovascular remodeling in the aged ischemic brain. J. Neural. Transm. (Vienna) 122:Suppl. 1 (2015), S25–S33.
12. [12] Hermann, D.M., ElAli, A., The abluminal endothelial membrane in neurovascular remodeling in health and disease. Sci. Signal., 5, 2012, re4.
13. [13] Holscher, C., Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221 (2014), T31–41.
14. [14] Holst, J.J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (2007), 1409–1439.
15. [15] Hou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J., Zhang, J.H., Liraglutide a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 32 (2012), 2201–2210.
16. [16] Lansberg, M.G., Bluhmki, E., Thijs, V.N., Efficacy and safety of tissue plasminogen activator 3–4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 40 (2009), 2438–2441.
17. [17] Larsen, P.J., Holst, J.J., Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul. Pept. 128 (2005), 97–107.
18. [18] Lee, C.H., Yan, B., Yoo, K.Y., Choi, J.H., Kwon, S.H., Her, S., Sohn, Y., Hwang, I.K., Cho, J.H., Kim, Y.M., Won, M.H., Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist exendin-4, in experimental transient cerebral ischemia. J. Neurosci. Res. 89 (2011), 1103–1113.
19. [19] Li, M., Li, S., Li, Y., Liraglutide promotes cortical neurite outgrowth via the MEK-ERK pathway. Cell. Mol. Neurobiol. 35 (2015), 987–993.
20. [20] Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K., Brossi, A., Lahiri, D.K., Mattson, M.P., Hoffer, B.J., Wang, Y., Greig, N.H., GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A 106 (2009), 1285–1290.
21. [21] Longa, E.Z., Weinstein, P.R., Carlson, S., Cummins, R., Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20 (1989), 84–91.
22. [22] Mergenthaler, P., Lindauer, U., Dienel, G.A., Meisel, A., Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 36 (2013), 587–597.
23. [23] Porter, W.D., Flatt, P.R., Hölscher, C., Gault, V.A., Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. Int. J. Obes. (Lond.) 37 (2013), 678–684.
24. [24] Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., Sasaki, T., Sasada, S., Kondo, A., Borlongan, C.V., Matsumae, M., Date, I., Neuroprotective effects of liraglutide for stroke model of rats. Int. J. Mol. Sci. 14 (2013), 21513–21524.
25. [25] Starke, R.D., Ferraro, F., Paschalaki, K.E., Dryden, N.H., McKinnon, T.A., Sutton, R.E., Payne, E.M., Haskard, D.O., Hughes, A.D., Cutler, D.F., Laffan, M.A., Randi, A.M., Endothelial von Willebrand factor regulates angiogenesis. Blood 117 (2011), 1071–1080.
26. [26] Xing, C., Hayakawa, K., Lok, J., Arai, K., Lo, E.H., Injury and repair in the neurovascular unit. Neurol. Res. 34 (2012), 325–330.
27. [27] Zhang, H., Song, F., Xu, C., Liu, H., Wang, Z., Li, J., Wu, S., Shen, Y., Chen, Y., Zhu, Y., Du, R., Tian, M., Spatiotemporal PET imaging of dynamic metabolic changes after therapeutic approaches of induced pluripotent stem cells, neuronal stem cells, and a chinese patent medicine in stroke. J. Nucl. Med. 56 (2015), 1774–1779.